Welcome to our dedicated page for Vigil Neuroscience news (Ticker: VIGL), a resource for investors and traders seeking the latest updates and insights on Vigil Neuroscience stock.
Vigil Neuroscience reports clinical-stage biotechnology developments in microglia-focused treatments for neurodegenerative diseases. Its updates have centered on TREM2 agonist programs, including iluzanebart, a monoclonal antibody TREM2 agonist studied in adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, and VG-3927, an oral small molecule TREM2 agonist developed with an initial focus on Alzheimer’s disease.
Recurring disclosures include clinical safety, tolerability, pharmacokinetic and pharmacodynamic data, scientific conference presentations, operating results, material agreements, governance matters and capital-structure updates. The company also reported Phase 2 IGNITE results for iluzanebart in ALSP and the discontinuation of the related long-term extension study after the trial showed no beneficial biomarker or clinical efficacy effects.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.